Session Title: Vascular Diseases and Diabetic Retinopathy II
Session Date/Time: Friday 12/09/2014 | 11:00-13:00
Paper Time: 11:08
Venue: Boulevard C
First Author: : V.Yarmak BELARUS
Co Author(s): : T. Imshenetskaya G. Vashkevich I. Malinovskaya
The aim of our study was to describe the clinical characteristics and management of patients with infectious endophthalmitis (EO) after intravitreal injection (IVI) of antivascular endothelial growth factor (VEGF) agent.
Belarusian Medical Academy of Post-Graduate Education Minsk, Belarus
The medical records of patients undergoing IVI VEGF bevacizumab (Avastin, Genentech) from October 1, 2009, through February 1, 2014, at a single medical academy clinic by two surgeons in operation room.
Five cases (5 patients) of infectious EO were identified after a total of 1820 injections (0,24%). All patients received pre- and postinjection topical antibiotics. All cases of EO presented within 3 days after the injection. All five patients complained of visual loss (hand motions or worse), without ocular pain. All our patients with EO were emergency treated with intravitreal antibiotic injections: four patients received only one injection Vancomycin and one patient - one injection Vancomycin and two injections Amikacin. We didn’t perform pars plana vitrectomy in our patients.
Infectious EO is a rare potential complication after IVI of VEGF. Timely performed intravitreal antibiotic injections permit to avoid pars plana vitrectomy and such severe complications as retinal detachment and phthisis.